Cardiovascular Events with Finerenone in Kidney Disease and Type 2 Diabetes

• Published in: The New England journal of medicine Vol. 385; no. 24; pp. 2252 - 2263
• Main Authors: Pitt, Bertram, Filippatos, Gerasimos, Agarwal, Rajiv, Anker, Stefan D, Bakris, George L, Rossing, Peter, Joseph, Amer, Kolkhof, Peter, Nowack, Christina, Schloemer, Patrick, Ruilope, Luis M
• Format: Journal Article
• Language: English
• Published: United States Massachusetts Medical Society 09.12.2021
• Subjects: Adverse events; Aged; Albumin; Albuminuria - etiology; Angiotensin; Cardiology; Cardiology General; Cardiovascular Diseases - epidemiology; Cardiovascular Diseases - mortality; Cardiovascular Diseases - prevention & control; Cerebral infarction; Chronic Kidney Disease; Clinical medicine; Congestive heart failure; Creatinine; Design; Diabetes; Diabetes mellitus (non-insulin dependent); Diabetes Mellitus, Type 2 - complications; Double-Blind Method; Endocrinology; Epidermal growth factor receptors; Female; Glomerular filtration rate; Heart failure; Hospitalization; Humans; Hyperkalemia; Kidney diseases; Male; Middle Aged; Mineralocorticoid Receptor Antagonists - adverse effects; Mineralocorticoid Receptor Antagonists - therapeutic use; Myocardial infarction; Naphthyridines - adverse effects; Naphthyridines - therapeutic use; Nephrology; Patient safety; Placebos; Potassium; Proportional Hazards Models; Renal failure; Renal Insufficiency, Chronic - complications; Renal Insufficiency, Chronic - drug therapy; Renin

In this double-blind trial, patients with stage 1 to 4 chronic kidney disease and type 2 diabetes were randomly assigned to receive finerenone or placebo. Finerenone treatment was superior with regard to the primary composite outcome of death from cardiovascular causes, nonfatal myocardial infarctio...